SG155046A1 - Process for modifying drug crystal formation - Google Patents

Process for modifying drug crystal formation

Info

Publication number: SG155046A1
Authority: SG; Singapore
Prior art keywords: crystal formation; drug crystal; modifying drug; modifying; crystals
Prior art date: 2003-01-20

Application number

SG200700660-4A

Other languages

English (en)

Inventor

Sabine Pfeffer

Dierk Wieckhusen

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-01-20

Filing date

2004-01-19

Publication date

2009-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9951448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG155046(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-01-19 Application filed by Novartis Ag filed Critical Novartis Ag

2009-09-30 Publication of SG155046A1 publication Critical patent/SG155046A1/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Transplantation (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)
Furan Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SG200700660-4A 2003-01-20 2004-01-19 Process for modifying drug crystal formation SG155046A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0301259.8A GB0301259D0 (en)	2003-01-20	2003-01-20	Organic compounds

Publications (1)

Publication Number	Publication Date
SG155046A1 true SG155046A1 (en)	2009-09-30

Family

ID=9951448

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG200700660-4A SG155046A1 (en)	2003-01-20	2004-01-19	Process for modifying drug crystal formation

Country Status (31)

Country	Link
US (3)	US20060122265A1 (es)
EP (2)	EP2308471A1 (es)
JP (1)	JP4549976B2 (es)
KR (5)	KR20100120321A (es)
CN (2)	CN101333201A (es)
AR (2)	AR043343A1 (es)
AT (1)	ATE546132T1 (es)
AU (1)	AU2004206731B2 (es)
BR (1)	BRPI0406827A (es)
CA (2)	CA2509796C (es)
CL (1)	CL2004000073A1 (es)
CO (1)	CO5580738A2 (es)
CY (1)	CY1112772T1 (es)
DK (1)	DK1592401T3 (es)
EC (1)	ECSP055918A (es)
ES (1)	ES2382035T3 (es)
GB (1)	GB0301259D0 (es)
IL (1)	IL169484A (es)
MX (1)	MXPA05007691A (es)
MY (1)	MY148297A (es)
NO (1)	NO20053846L (es)
NZ (1)	NZ541073A (es)
PE (2)	PE20040826A1 (es)
PL (2)	PL376525A1 (es)
PT (1)	PT1592401E (es)
RU (1)	RU2388757C2 (es)
SG (1)	SG155046A1 (es)
SI (1)	SI1592401T1 (es)
TW (1)	TWI325785B (es)
WO (1)	WO2004064806A2 (es)
ZA (1)	ZA200504442B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0124953D0 (en)	2001-10-17	2001-12-05	Novartis Ag	Organic Compounds
GB0301259D0 (en)	2003-01-20	2003-02-19	Novartis Ag	Organic compounds
AR045957A1 (es) *	2003-10-03	2005-11-16	Novartis Ag	Composicion farmaceutica y combinacion
TW200613294A (en)	2004-04-26	2006-05-01	Teva Gyogyszergyar Reszvenytarsasag	Process for preparation of mycophenolic acid and ester derivatives thereof
MXPA06005658A (es)	2004-04-27	2007-04-10	Teva Gyogyszergyar Zartkoruen	Proceso para preparacion de micofenolato mofetil, y otros esteres de acido micofenolico.
EP1699773A2 (en)	2004-07-20	2006-09-13	Ceva Gyogyszergyar R Szv Nytarsasag	Processes for preparation of crystalline mycophenolate sodium
GB0419355D0 (en) *	2004-08-31	2004-09-29	Novartis Ag	Organic compounds
US20080176937A1 (en) *	2007-01-23	2008-07-24	Apotex Fermentation Inc.	Novel crystalline mycophenolate sodium polymorph and processes to manufacture same
TR201106844T2 (tr) *	2008-10-09	2012-02-21	Abd� �Brah�M �La� Sanay� Ve T�Caret Anon�M ��Rket�@	Moksi̇floksasi̇n yaş granülasyonunda organi̇k solventleri̇n kullanimi.
CN101756958B (zh) *	2008-11-10	2011-07-20	鲁南制药集团股份有限公司	一种治疗关节炎的药物组合物及其制备方法
US20110009347A1 (en)	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
DK2451797T3 (da) *	2009-07-10	2013-06-24	Janssen Pharmaceutica Nv	Fremgangsmåde til krystallisation for 1-(b-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-fluorphenyl)-2- thienylmethyl]benzen
EA201270544A1 (ru) *	2009-10-13	2012-09-28	Тева Фармасьютикал Индастриз Лтд.	Композиции с отсроченным высвобождением
SG10201500639TA (en)	2010-01-27	2015-03-30	Arena Pharm Inc	Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
NZ703128A (en)	2010-05-11	2016-04-29	Janssen Pharmaceutica Nv	Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
CN103880799A (zh) *	2010-11-16	2014-06-25	北京京卫信康医药科技发展有限公司	麦考酚酸钠的新晶型及其制备方法
CN103880800A (zh) *	2010-11-16	2014-06-25	北京京卫信康医药科技发展有限公司	麦考酚酸钠的新晶型及其制备方法
EP2697218B1 (en)	2011-04-13	2016-05-25	Janssen Pharmaceutica NV	Process for the preparation of compounds useful as inhibitors of sglt2
TWI582078B (zh) *	2013-01-23	2017-05-11	北京貝美拓新藥研發有限公司	抑制脯氨酸羥化酶活性的化合物的晶型及其應用
JP6838744B2 (ja)	2015-06-22	2021-03-03	アリーナファーマシューティカルズ，インコーポレイテッド	Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
US20170071970A1 (en)	2015-09-15	2017-03-16	Janssen Pharmaceutica Nv	Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
HUE049895T2 (hu) *	2015-12-21	2020-11-30	Janssen Pharmaceutica Nv	Kristályosítási eljárás kanagliflozin hemihidrát kristályok elõállítására
AU2018220521A1 (en)	2017-02-16	2019-09-05	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of primary biliary cholangitis
CA3053416A1 (en)	2017-02-16	2018-08-23	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
CN108727317A (zh) *	2017-04-25	2018-11-02	鲁南制药集团股份有限公司	一种麦考酚酸的晶型物
CN108727318A (zh) *	2017-04-25	2018-11-02	鲁南制药集团股份有限公司	麦考酚酸的晶型物
KR102859841B1 (ko)	2018-06-06	2025-09-12	아레나 파마슈티칼스, 인크.	S1p1 수용체와 관련된 병태의 치료 방법
CN110922371B (zh) *	2019-12-27	2020-08-11	广东蓝宝制药有限公司	一种m2晶型麦考酚钠的制备方法
TWI858258B (zh)	2020-05-18	2024-10-11	瑞士商諾華公司	Ｌｎｐ０２３之結晶形式
CN119173494A (zh) *	2022-05-31	2024-12-20	本州化学工业株式会社	4,4’-双（1,1-双（4-羟基-3-甲基苯基）乙基）联苯的结晶及其制造方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2145074A (en) *	1983-06-16	1985-03-20	Shiraishi Central Lab Co Ltd	Calcium carbonate
US5531922A (en) *	1992-08-04	1996-07-02	Toda Kogyo Corporation	Granulated particles for magnetic particles for magnetic recording, and process for producing the same
JPH09209297A (ja) *	1996-01-26	1997-08-12	Nippon Paper Ind Co Ltd	艶消し軽量塗工紙及びその製造方法
AU747887B2 (en) *	1998-06-24	2002-05-30	Sanofi-Synthelabo	Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US158835A (en) *		1875-01-19		Improvement in mortising-tools
GB935432A (en) *	1958-05-29	1963-08-28	Secr Aviation	Improvements in the manufacture of crystalline substances
US3183263A (en) *	1962-10-19	1965-05-11	Commercial Solvents Corp	Method for changing the crystal habit of mono-sodium glutamate
US3187039A (en) *	1962-10-19	1965-06-01	Commercial Solvents Corp	Method for changing the crystal habit of monosodium glutamate
US3352906A (en) *	1963-02-04	1967-11-14	Charles R Parkerson	Habit modification and preparation of single crystal triglycine sulfate
GB1157099A (en) *	1966-09-27	1969-07-02	Ici Ltd	Fermentation Process
GB1157100A (en) *	1966-09-27	1969-07-02	Ici Ltd	Pharmaceutical Compositions
US3770390A (en) *	1971-02-26	1973-11-06	Dow Chemical Co	Crystal habit modification of inorganic salts using polymeric sulfonates or sulfates
US4259239A (en) *	1980-04-21	1981-03-31	Allied Chemical Corporation	Resolution of enantiomeric complexes of nickelous chloride and alpha-aminocaprolactam
IL60254A (en)	1980-06-08	1983-11-30	Yeda Res & Dev	Resolution of amino acids
JPS5875194A (ja) *	1981-10-30	1983-05-06	株式会社日立製作所	マトリクス表示装置及び駆動方法
IL77031A (en)	1985-11-12	1995-12-08	Yeda Res & Dev	Kinetic resolution of racemic mixtures by polymer-bound crystallization inhibitors
JPH0745359B2 (ja)	1987-12-25	1995-05-17	東レ株式会社	有機化合物結晶の製造方法
DE69414720T2 (de)	1993-09-15	1999-04-08	Syntex (U.S.A.) Inc., Palo Alto, Calif.	Kristallines, wasserfreies mofetilmycophenolat und zubereitungen zu deren intravenösen anwendung
KR100491274B1 (ko) *	1996-04-12	2005-09-05	노파르티스 아게	미코페놀레이트의장용코팅된약제조성물
ID18663A (id)	1996-04-12	1998-04-30	Novartis Ag	Komposisi farmasi berlapis enterik
GB0301259D0 (en) *	2003-01-20	2003-02-19	Novartis Ag	Organic compounds

2003
- 2003-01-20 GB GBGB0301259.8A patent/GB0301259D0/en not_active Ceased
2004
- 2004-01-19 CN CNA2008101443548A patent/CN101333201A/zh active Pending
- 2004-01-19 KR KR1020107024515A patent/KR20100120321A/ko not_active Ceased
- 2004-01-19 KR KR1020077016703A patent/KR20070087181A/ko not_active Ceased
- 2004-01-19 AU AU2004206731A patent/AU2004206731B2/en not_active Expired
- 2004-01-19 AT AT04703158T patent/ATE546132T1/de active
- 2004-01-19 CA CA2509796A patent/CA2509796C/en not_active Expired - Lifetime
- 2004-01-19 JP JP2005518641A patent/JP4549976B2/ja not_active Expired - Fee Related
- 2004-01-19 KR KR1020097022060A patent/KR20090115821A/ko not_active Ceased
- 2004-01-19 MX MXPA05007691A patent/MXPA05007691A/es active IP Right Grant
- 2004-01-19 PE PE2004000074A patent/PE20040826A1/es not_active Application Discontinuation
- 2004-01-19 BR BR0406827-0A patent/BRPI0406827A/pt not_active Application Discontinuation
- 2004-01-19 MY MYPI20040142A patent/MY148297A/en unknown
- 2004-01-19 TW TW093101302A patent/TWI325785B/zh not_active IP Right Cessation
- 2004-01-19 RU RU2005126328/04A patent/RU2388757C2/ru active
- 2004-01-19 ES ES04703158T patent/ES2382035T3/es not_active Expired - Lifetime
- 2004-01-19 EP EP10177718A patent/EP2308471A1/en not_active Withdrawn
- 2004-01-19 DK DK04703158.8T patent/DK1592401T3/da active
- 2004-01-19 PT PT04703158T patent/PT1592401E/pt unknown
- 2004-01-19 AR ARP040100142A patent/AR043343A1/es unknown
- 2004-01-19 CA CA2706900A patent/CA2706900A1/en not_active Abandoned
- 2004-01-19 SI SI200431859T patent/SI1592401T1/sl unknown
- 2004-01-19 NZ NZ541073A patent/NZ541073A/en not_active IP Right Cessation
- 2004-01-19 PE PE2011000069A patent/PE20110276A1/es active IP Right Grant
- 2004-01-19 US US10/541,504 patent/US20060122265A1/en not_active Abandoned
- 2004-01-19 KR KR1020057013313A patent/KR100855149B1/ko not_active Expired - Lifetime
- 2004-01-19 PL PL376525A patent/PL376525A1/pl not_active Application Discontinuation
- 2004-01-19 CN CN200480002455A patent/CN100595199C/zh not_active Expired - Lifetime
- 2004-01-19 SG SG200700660-4A patent/SG155046A1/en unknown
- 2004-01-19 KR KR1020097022061A patent/KR101129105B1/ko not_active Expired - Lifetime
- 2004-01-19 PL PL393385A patent/PL213192B1/pl unknown
- 2004-01-19 EP EP04703158A patent/EP1592401B1/en not_active Revoked
- 2004-01-19 WO PCT/EP2004/000354 patent/WO2004064806A2/en not_active Ceased
- 2004-01-20 CL CL200400073A patent/CL2004000073A1/es unknown
2005
- 2005-05-31 ZA ZA200504442A patent/ZA200504442B/en unknown
- 2005-06-30 IL IL169484A patent/IL169484A/en active IP Right Grant
- 2005-07-15 EC EC2005005918A patent/ECSP055918A/es unknown
- 2005-07-25 CO CO05072728A patent/CO5580738A2/es not_active Application Discontinuation
- 2005-08-16 NO NO20053846A patent/NO20053846L/no not_active Application Discontinuation
2008
- 2008-12-18 US US12/337,663 patent/US8008511B2/en not_active Expired - Lifetime
2011
- 2011-08-04 US US13/198,022 patent/US8124795B2/en not_active Expired - Lifetime
2012
- 2012-05-14 CY CY20121100450T patent/CY1112772T1/el unknown
2016
- 2016-02-15 AR ARP160100409A patent/AR103711A2/es not_active Application Discontinuation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2145074A (en) *	1983-06-16	1985-03-20	Shiraishi Central Lab Co Ltd	Calcium carbonate
US5531922A (en) *	1992-08-04	1996-07-02	Toda Kogyo Corporation	Granulated particles for magnetic particles for magnetic recording, and process for producing the same
JPH09209297A (ja) *	1996-01-26	1997-08-12	Nippon Paper Ind Co Ltd	艶消し軽量塗工紙及びその製造方法
AU747887B2 (en) *	1998-06-24	2002-05-30	Sanofi-Synthelabo	Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same

Also Published As

Publication number	Publication date
CA2509796A1 (en)	2004-08-05
PT1592401E (pt)	2012-05-10
ATE546132T1 (de)	2012-03-15
BRPI0406827A (pt)	2005-12-27
AU2004206731B2 (en)	2008-03-20
KR20090115821A (ko)	2009-11-06
EP1592401B1 (en)	2012-02-22
ECSP055918A (es)	2005-11-22
KR20100120321A (ko)	2010-11-15
TWI325785B (en)	2010-06-11
PE20040826A1 (es)	2004-12-23
CY1112772T1 (el)	2016-02-10
AU2004206731A8 (en)	2004-08-05
JP2006515016A (ja)	2006-05-18
GB0301259D0 (en)	2003-02-19
HK1084874A1 (en)	2006-08-11
KR20070087181A (ko)	2007-08-27
PL393385A1 (pl)	2011-03-14
ZA200504442B (en)	2006-02-22
US8008511B2 (en)	2011-08-30
PE20110276A1 (es)	2011-05-27
AU2004206731A1 (en)	2004-08-05
US20060122265A1 (en)	2006-06-08
WO2004064806A2 (en)	2004-08-05
IL169484A (en)	2016-03-31
KR20050096940A (ko)	2005-10-06
RU2388757C2 (ru)	2010-05-10
AR103711A2 (es)	2017-05-31
EP2308471A1 (en)	2011-04-13
KR101129105B1 (ko)	2012-04-12
JP4549976B2 (ja)	2010-09-22
KR100855149B1 (ko)	2008-08-28
RU2005126328A (ru)	2006-07-27
MXPA05007691A (es)	2005-09-30
WO2004064806A3 (en)	2004-10-28
CO5580738A2 (es)	2005-11-30
CL2004000073A1 (es)	2005-01-14
EP1592401A2 (en)	2005-11-09
AR043343A1 (es)	2005-07-27
MY148297A (en)	2013-03-29
PL376525A1 (pl)	2006-01-09
TW200505505A (en)	2005-02-16
CA2706900A1 (en)	2004-08-05
DK1592401T3 (da)	2012-05-21
CN101333201A (zh)	2008-12-31
PL213192B1 (pl)	2013-01-31
CN1738605A (zh)	2006-02-22
KR20090115898A (ko)	2009-11-09
CA2509796C (en)	2010-09-14
IL169484A0 (en)	2007-07-04
US20090209639A1 (en)	2009-08-20
ES2382035T3 (es)	2012-06-04
NO20053846L (no)	2005-08-16
US8124795B2 (en)	2012-02-28
US20110288313A1 (en)	2011-11-24
CN100595199C (zh)	2010-03-24
SI1592401T1 (sl)	2012-05-31
NZ541073A (en)	2008-12-24

Publication	Publication Date	Title
TW200505505A (en)	2005-02-16	Process for modifying drug crystal formation
MXPA05010712A (es)	2005-12-15	Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias.
SE0200920D0 (sv)	2002-03-25	Novel compounds
CY1118637T1 (el)	2017-07-12	Νεα κρυσταλλικη μορφη iii της αγομελατινης, μεθοδος παρασκευης αυτης και οι φαρμακευτικες συνθεσεις που την περιεχουν
WO2006086562A3 (en)	2007-03-22	Phenylazetidinone derivatives
EA200602191A1 (ru)	2007-06-29	5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
WO2005037798A3 (en)	2005-06-16	Amide or thiomide derivatives and their use in the treatment of pain
WO2006099941A8 (de)	2006-11-09	Aminocarbonyl substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
CY1109569T1 (el)	2014-08-13	Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
ZA200506422B (en)	2007-02-28	Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use of the same as medicaments, and medicament containing such compounds
DE502004008819D1 (de)	2009-02-26	Medikament zur wachstumsinhibierung von tumoren
WO2004087880A8 (en)	2005-01-13	Compounds and their use to treat diabetes and related disorders
WO2004019879A3 (en)	2004-06-03	Motilide compounds
WO2005046727A3 (en)	2005-08-25	Ibuprofen-containing soft gelatin capsules
CY1110156T1 (el)	2015-01-14	Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
NO20053673L (no)	2005-09-30	Nye antikonvulsanderivatsalter
WO2004033416A3 (de)	2004-05-13	Carboxyalkoxy-substituierte acyl-carboxyphenyl-harnstoffderivate, verfahren zu ihre herstellung und ihre verwendung als arzneimittel
ATE505193T1 (de)	2011-04-15	Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
MX2007010841A (es)	2007-11-09	8-pirrolidinobenzimidazoles biciclicos sustituidos, un metodo para su produccion y su uso como medicamentos.
WO2005049024A3 (de)	2006-03-30	Feste pharmazeutische zubereitungsform
WO2005020911A3 (en)	2005-07-21	Benzo[1, 3]dioxole compounds, pharmaceutical compositions thereof, and processes of making and using the same
SE0400522D0 (sv)	2004-03-01	A medical solution, a method for producing said medical solution and use thereof
WO2005054174A3 (de)	2005-08-11	Verbindungen zur modulation des glykolyse-enzym-und/oder transaminase-komplexes
ATE345124T1 (de)	2006-12-15	Verwendung von l-acetylcarnitin zur herstellung eines medikaments zur behandlung von anhedonia
WO2004069840A3 (de)	2004-12-02	Herstellung von tetrahydrochinolinbenzofuranen